Drug intelligence / Profile preview

Suven multimodal dopaminergic and serotonergic modulator

Development stage: Preclinical
Lead developer: Suven Life Sciences
Modality: Small Molecules
Administration: Oral, Intravenous, Subcutaneous, Intranasal, Sublingual, Topical, Intrathecal, Intraarterial, Intracerebroventricular

Overview

Suven's multimodal dopaminergic and serotonergic receptor modulator is an unnamed small molecule currently in preclinical development for the treatment of bipolar disorders. Developed by Suven Life Sciences, the compound is designed to target multiple receptor subtypes within both the dopamine and serotonin neurotransmitter systems. This multimodal approach aims to provide a more comprehensive therapeutic effect for psychiatric conditions characterized by complex neurochemical dysregulation, such as bipolar disorder, compared to agents targeting a single receptor or system. The asset is part of Suven's broader CNS-focused discovery program and is distinct from their clinical-stage serotonin/dopamine modulator, SUVN-M8036.

Other names: Multimodal dopaminergic and serotonergic receptor modulatorSuven Life Sciences-Dopaminergic and serotonergic receptors (multimodal)-small molecule-Bipolar Disorders

Targets

HTR7 (5-hydroxytryptamine receptor 7)HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on Suven multimodal dopaminergic and serotonergic modulator.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suven multimodal dopaminergic and serotonergic modulator.

Explore the full profile